RecruitingNCT06834152

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer in Patients With Lower Urinary Tract Symptoms and/or Prostate Hyperplasia (X-SMILE)

Sponsor

University of Zurich

Enrollment

75 participants

Start Date

Mar 1, 2024

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer (Adenocarcinoma)Localized Prostate Carcinoma Prostate Hyperplasia Lower Urinary Track Symptoms

Summary

The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and/or prostatic hyperplasia.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two radiation delivery schedules — 2 sessions versus the standard 5 sessions — for prostate cancer using highly precise, image-guided stereotactic body radiotherapy (SBRT). Researchers want to know if 2 sessions is just as effective and safe as 5 sessions. **You may be eligible if...** - You have been diagnosed with localized prostate cancer (confirmed by biopsy) - Your cancer is classified as low or intermediate risk - Your planned treatment already involves SBRT - You are 18 or older with a good performance status **You may NOT be eligible if...** - You have high-risk or very high-risk prostate cancer - You have had prior pelvic radiation - You have an implanted device (like a pacemaker) that is not compatible with radiation planning - You are unable to complete required follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONradiotherapy

Patients with prostate cancer in the medium or high risk range who are planned to receive definitive CT or MRI-adaptive SBRT.

Locations(3)

Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg

Heidelberg, Baden-Wurttemberg, Germany

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum LMU

Munich, Bavaria, Germany

University Hospital Zurich, Department of Radio-Oncology

Zurich, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06834152

Related Trials

Outcome and Patient Experiences After Transurethral Resection and Bipolar Enucleation of the Prostate - a Multi-center, Randomized Controlled Trial.

NCT075623862 locations

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT025263681 location

Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate

NCT066493576 locations

e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters

NCT069058081 location

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

NCT068443832 locations